Soligenix receives japanese patent for improved production of synthetic hypericin composition

Princeton, n.j., may 20, 2021 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the japan patent office has allowed the patent application titled "systems and methods for producing synthetic hypericin".
SNGX Ratings Summary
SNGX Quant Ranking